Información del artículo
La angiopatía es una complicación muy frecuente en los diabéticos. El daño endotelial multicausal origina tanto la micro como la macroangiopatía. La disfunción del endotelio sería la primera fase de la secuencia patogénica. Existe una serie de marcadores bioquímicos, morfológicos y funcionales que permiten su detección en estadios iniciales. Aunque en la retinopatía diabética ha sido ampliamente analizado el papel del factor de crecimiento del endotelio vascular (VEGF), parece que también puede tener una intervención en otras complicaciones vasculares, como son la nefropatía, la neuropatía y la macroangiopatía. Recientemente se han comenzado a ensayar tratamientos que modulan la acción de ese factor; sin embargo, las consecuencias que podrían derivarse sobre algunos territorios, como el coronario y el retiniano, pueden ser contrapuestas.
Palabras clave:
Disfunción endotelial
Macroangiopatía
Microangiopatía
Diabetes mellitus
Factor de crecimiento del endotelio vascular
Vascular complications are the main causes of morbidity and mortality in patients with diabetes. Several lines of evidence suggest that endothelial damage and angiogenic factors, could play a key role in the development of both micro-and macroangiopathy. Great progress has been achieved in elucidating the fundamental processes underlying the pathogenesis of these complications. Several markers are used to estimate the risl of endothelial dysfunction. The angiogenic response accounts for much of the diabetic retinopathy and may, in addition, serve a significant role in nephropathy and neuropathy. In contrast, recent data suggest that vascular collateralization resulting from ischemia-induced growth factor release in tissues compromised by macrovascular disease may be important in reducing clinical symptoms and tissue damage. Thus, two apparently diametrically opposed pathogenetic paradigms are arising, which complicate the actual understanding of these phenomena, generating a perplexing paradox, which necessitates careful consideration of the potential risks, benefits, and interactions arising from the probable future used of therapeutic approaches with growth factor agonists and antagonists.
Key words:
Endothelial dysfunction
Macroangiopathy
Microangiopaty
Diabetes mellitus
Vascular endothelial growth factor
El Texto completo está disponible en PDF
Bibliografía
[1.]
K.C. Donaghue, J. Robinson, R. McCredie, A. Fung, M. Silink, D.S. Celermajer.
Larg e vessel dysfunction in diabetic adolescents and its relationship to small vessel complications.
J Pediatr Endocrinol Metab, 10 (1997), pp. 593-598
[2.]
M.F. Lopes-Virella, G. Virella.
Cytokinez, modified lipoproteins, and arteriosclerosis in diabetes.
Diabetes, 45 (1996), pp. 40-44
[3.]
M. Lu, M. Kuroki, S. Amano, M. Toletino, K. Keough, I. Kim, et al.
Advanced glycation end products increase retinal vascular endothelial growth factor expression.
J Clin Invest, 101 (1998), pp. 1219-1224
[4.]
M.A. Hoffmann, B. Koh, M.S. Zumbach, V. Borceau, A. Bierhaus, M. Henkels, et al.
Hyperhomcysteinemia and endothelial dysfunction in IDDM.
Diabetes Care, 21 (1998), pp. 841-848
[5.]
J.M. Fernández-Real, M. Broch, J.M. Vendrell, C. Gutiérrez, R. Casamitjana, M. Pugeat, et al.
Interleukin-6 gen polymorphism and insulin sensitivity.
Diabetes, 49 (2000), pp. 517-520
[6.]
J.E. Tooke, M.M. Hannemann.
Adverse endothelial function and insulin resistance syndrome.
J Intern Med, 247 (2000), pp. 425-431
[7.]
L. Poston.
Endothelial control of vascular tone in diabetes mellitus.
Diabetologia, 40 (1997), pp. S113-S114
[8.]
Stejouwer ACD.
Is measurement of endothelial dysfunction clinically useful?.
Eur J Clin Invest, 29 (1999), pp. 459-461
[9.]
M. Ricote, J. Huang, A. Fajas Li, J. Welch, L. Najib, et al.
Expression of the peroxinome proliferator-activated receptor gamma (PPAR gamma) in human atherosclerosis and regulation un macrophages by colony stimulating factors and oxidezed low density lipoprotein.
Proc Natl Acad Sci USA, 95 (1998), pp. 7614-7619
[10.]
M.T. Johnstone, S.J. Creager, K.M. Scales, J.A. Cusco, B.K. Lee, M.A. Creager.
Impaired endothelium-dependent vasodilatation in patients with insulin-dependent diabetes mellitus.
Circulation, 88 (1993), pp. 2510-2516
[11.]
K.B. Stansberry, S.A. Shapiro, M.A. Hill, P.M. McNitt, M.D. Meyer, A.I. Vinik.
Impaired peripheral vasomotion in diabetes.
Diabetes Care, 19 (1996), pp. 715-721
[12.]
W.A. Hsued, P.W. Anderson.
Hypertension, the endothelial cell, and the vascular complications of diabetes mellitus.
Hypertension, 20 (1992), pp. 253-263
[13.]
J. Danesh, R. Collins, P. Appleby, R. Peto.
Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart diaseas.
JAMA, 279 (1998), pp. 1477-1482
[14.]
P. Vallance, J. Collien, K. Bhagat.
Infection, inflammation, and infarction: does acute endothelial dysfunction provide a link?.
Lancet, 349 (1997), pp. 1391-1392
[15.]
P.M. Ridker, M. Cushman, M.J. Stampfer, R.P. Tracy, C.H. Hennekens.
Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease.
Circulation, 97 (1998), pp. 425-428
[16.]
C.G. Schalkwijk, DCW Poland, E. Van Dijk, A. Kok, J.J. Emeis, A.M. Dräger, et al.
Plasma concentration of C-reactive protein is increased in type I diabetic patients without without clinical marcoangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation.
Diabetologia, 42 (1999), pp. 351-357
[17.]
J. Danesh, R. Collins, R. Peto.
Chronic infections and coronary heart disease: is there a link?.
Lancet, 350 (1997), pp. 430-436
[18.]
A. Sobol.
Fibrinogen level in patients with type I diabetes with and without retinopathy.
Acta Haematol Pol, 26 (1999), pp. 57-62
[19.]
L.P. Aiello, R.L. Avery, P.G. Arrigg, B. Keyt, L.M. Aiello, H.D. Jampel, et al.
Vascular endithelial growth factor in ocular fluid of patients with diabetic retinopathy and other disorders.
N Engl J Med, 331 (1994), pp. 1480-1494
[20.]
L.P. Aiello, S.E. Bursell, A. Clermont, E. Duh, H. Ishii, C. Takagi, et al.
Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effctive betaisoform-selective inhibitor.
Diabetes, 46 (1997), pp. 1473-1480
[21.]
M. Boulton, D. Foreman, G. Williams, D. McLeod.
VEGF localisation in diabetic retinopathy.
Brit J Ophtalmolog, 82 (1998), pp. 561-568
[22.]
L.E. Smith, E. Wesolowski, A. McLellan, S.K. Kostyk, R. D'Amato, R. Sullivan, et al.
Oxygen-induced retinopathy in the mouse.
Invest Ophtalmolog Vis Sci, 36 (1995), pp. 2063-2070
[23.]
P.L. Lip, F. Belgore, A.D. Blann, Mw Hope-Ross, J.M. Gibson, G.Y. Lip.
Plasma VEGF and soluble VEGF receptor FLT-1 in proliferative retinopathy: relationship to endothelial dysfunction and lasser treatment.
Invest Ophtalmol Vis Sci, 41 (2000), pp. 2115-2119
[24.]
R. Burgos, R. Simo, L. Audi, C. Mateo, J. Mesa, M. Garcia-Ramírez, et al.
Vitreus levels of vascular endothelial growth factor are not influenced by its serum concentrations in diabetic retinopathy.
Diabetologia, 40 (1997), pp. 1107-1109
[25.]
A. Schultz, L. Lavie, R. Beyar, T. Stone, K. Skorecki, P. Lavie, et al.
Interindividual heterogeneity in the hipoxic regulation of VEGF: significance for the development of the coronary artery collateral circulation.
Circulation, 100 (1999), pp. 547-552
[26.]
P. Hivind, L. Tarnow, P.B. Oestergaard, H.H. Parving.
Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic neophropathy.
Kidney Int, 57 (2000), pp. S56-S61
[27.]
L. Kessler, M.L. Wiese, P. Attali, J.M. Mossard, J.P. Cazenave, M. Pinget.
Von Willebrand factor in diabetic angiopathy.
Diabetes Metab, 24 (1998), pp. 327-336
[28.]
B.B. Duncan, M.I. Schmidt, S. Offenbacher, K.K. Wu, P.J. Savage, G. Heiss.
Factor VIII and other hemostasis variables are related to incident diabetes in adults. The atherosclerosis risk in communities (ARIC) study.
Diabetes Care, 22 (1999), pp. 767-772
[29.]
D.S. Celermajer, K.E. Sorensen, V.M. Gooch, D.J. Spiegelhalter, O.I. Miller, I.D. Sullivan, et al.
Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis.
Lancet, 340 (1992), pp. 1111-1115
[30.]
E. Dult, L.P. Aiello.
Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox.
Diabetes, 48 (1999), pp. 1899-1906
[31.]
K.E. Sorensen, D.S. Xceler, D.J. Spiegelhalte, D. Georgakopoulios, J. Robinson, O. Thomas, et al.
Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproductibility.
B Heart J, 74 (1995), pp. 247-253
[32.]
R.A. Vogel.
Brachial artery ultrasound: a noninvasive tool in the assessment of triglyceride-rich lipoproteins.
Clin Cardiol, 2 (1999), pp. 1134-1139
[33.]
P. Poredos, A. Kek.
Relation of blunted dilatation of the brachial artery in insulin-dependent diabetes mellitus to microalbuminuria.
Am J Cardiol, 86 (2000), pp. 364-367
[34.]
R. Predinelli, O. Gampietro, F. Carmassi, E. Melillo, G. Dell'Olmo, G. Catapano, et al.
Microalbuminuria and endothelial dysfunction in essential hypertension.
Lancet, 344 (1994), pp. 14-18
[35.]
D.R. Senger, D.T. Connolly, L. Van de Water, H.F. Feder J Dvorak.
Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor.
Cancer Res, 50 (1990), pp. 1774-1778
[36.]
M. Simon, W. Rockl, C. Hornig, E.F. Grone, H. Theis, H.A. Weich, et al.
Receptors of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in fetal and adult human kidney.
Am J Physiol, 268 (1995), pp. F240-F250
[37.]
A. Samii, J. Unger, W. Lange.
Vascular endothelial growth factor expression in peripheral nerves and dorsal root ganglia in diabetic neuropathy in rats.
Neurosci Lett, 262 (1999), pp. 159-162
[38.]
S. Banay, M.T. Jaklitsch, M. Shou, D.F. Lazarous, M. Scheinowitz, S. Biro, et al.
Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs.
Circulation, 89 (1994), pp. 2183-2189
[39.]
D.W. Losordo, P.R. Vale, J.F. Symes, C.H. Dunnington, D.D. Esakof, M. Mayski, et al.
Gene therapy for myocardial angiogenesis initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia.
Circulation, 98 (1998), pp. 2800-2804
[40.]
K.J. Kim, B. Li, J. Winer, M. Armanini, N. Gillet, H.S. Phillips, et al.
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo.
Nature, 362 (1993), pp. 841-844
[41.]
B.M. Kenyon, F. Brown, R.J. D'Amato.
Effects of thalidomide and related metabolites in a mouse corneal model of neovascularitation.
Exp Eye Res, 64 (1997), pp. 971-978
[42.]
I. Baumgartner, A. Pieczek, O. Manor, R. Blair, M. Kearney, K. Walsh, et al.
Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia.
Circulation, 97 (1998), pp. 1114-1123
Copyright © 2001. Sociedad Española de Endocrinología y Nutrición
